Orexo Logo

Orexo

Develops pharmaceuticals and digital therapies for substance use and mental health.

ORX | ST

Overview

Corporate Details

ISIN(s):
SE0000736415 (+2 more)
LEI:
549300LJ5CCWDPTK9Z08
Country:
Sweden
Address:
Box 303, 751 05 UPPSALA

Description

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-23 08:00 Swedish 4.8 MB
2025-10-23 08:00 English 4.8 MB
2025-10-17 08:00
Orexo:s valberedning inför årsstämman 2026
Swedish 78.0 KB
2025-10-17 08:00
Orexo´s Nomination Committee for the Annual General Meeting 2026
English 77.7 KB
2025-10-06 15:35 Swedish 9.8 KB
2025-09-29 20:30
Orexo US Awarded USD 8 Million by BARDA for OX390 Development Partnership
English 86.4 KB
2025-09-29 20:30
Orexo US får SEK 75 miljoner från BARDA för utvecklingssamarbete kring OX390 mo…
Swedish 88.2 KB
2025-07-16 08:00 Swedish 6.7 MB
2025-07-16 08:00 English 6.6 MB
2025-06-30 17:30
Antal aktier och röster i Orexo
Swedish 76.3 KB
2025-06-30 17:30
Number of shares and votes in Orexo
English 76.6 KB
2025-06-25 11:38 Swedish 9.8 KB
2025-06-19 16:40 Swedish 9.9 KB
2025-06-18 18:00
Emission och återköp av C-aktier
Swedish 166.4 KB
2025-06-18 18:00
Issue and repurchase of class C shares
English 168.1 KB

Automate Your Workflow. Get a real-time feed of all Orexo filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Orexo

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Orexo via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-11 Nikolaj Arrild Sørensen Other Buy 2,460 35,178.00 SEK
2025-04-04 Nikolaj Arrild Sørensen Other Buy 3,500 47,530.00 SEK
2024-03-26 Fredrik Järrsten Other Buy 3,000 44,040.00 SEK
2023-11-24 Charlotte Vithlani Hansson Other Buy 3,000 44,640.00 SEK
2023-11-08 Fredrik Järrsten Other Buy 1,500 23,715.00 SEK
2023-02-24 Nikolaj Arrild Sørensen Other Buy 11,500 188,945.00 SEK
2023-01-27 Fredrik Järrsten Other Buy 4,500 79,695.00 SEK
2022-07-26 Michael Matly Other Buy 2,820 60,777.77 SEK
2022-07-21 Charlotte Vithlani Hansson Other Buy 3,000 61,500.00 SEK
2022-07-15 James Noble Other Buy 18,500 394,252.80 SEK

Peer Companies

Annexon, Inc. Logo
Clinical-stage biopharma developing complement medicines by inhibiting C1q.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes cell therapies and orphan drugs using adult stem cells.
South Korea
065660
Antibiotice S.A. Logo
Pharmaceutical firm manufacturing generic medicines, anti-infectives, and APIs.
Romania
ATB
Apellis Pharmaceuticals, Inc. Logo
Biopharmaceutical company developing therapies by targeting the complement cascade.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Clinical-stage biopharma developing a bee venom drug and AI digital treasury solutions.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Clinical-stage biotech developing biologics for immunological and inflammatory diseases.
United States of America
APGE
Apollomics Inc. Logo
Clinical-stage biotech developing innovative oncology and combination therapies.
United States of America
APLM
Apontis Pharma AG Logo
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
Germany
APPH
Applied Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel drugs for rare metabolic and CNS diseases.
United States of America
APLT
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologics and biosimilar antibody-based therapeutics.
South Korea
003060

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.